StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. (ROIV) stock

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.71+0.10 (+0.26%)

Close on Nov 17, 2026Market cap $27.96BP/E –Yield –

Roivant Sciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Roivant Sciences's total debt was $12.00M at Jun 30, 2024. For fiscal 2023 it was $12.00M, down 70.5% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2023Mar 31, 2024$12.00M-70.5%
FY2022Mar 31, 2023$40.72M-80.6%
FY2021Mar 31, 2022$210.03M+23.3%
FY2020Mar 31, 2021$170.28M–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2024CQ2 2024Jun 30, 2024$12.00M-73.0%
Q4 FY2023CQ1 2024Mar 31, 2024$12.00M-70.5%
Q3 FY2023CQ4 2023Dec 31, 2023$45.71M+21.2%
Q2 FY2023CQ3 2023Sep 30, 2023$49.00M+37.0%
Q1 FY2023CQ2 2023Jun 30, 2023$44.41M+33.3%
Q4 FY2022CQ1 2023Mar 31, 2023$40.72M-80.6%
Q3 FY2022CQ4 2022Dec 31, 2022$37.72M-81.5%
Q2 FY2022CQ3 2022Sep 30, 2022$35.75M-82.1%
Q1 FY2022CQ2 2022Jun 30, 2022$33.30M-82.1%
Q4 FY2021CQ1 2022Mar 31, 2022$210.03M+23.3%
Q3 FY2021CQ4 2021Dec 31, 2021$204.04M–
Q2 FY2021CQ3 2021Sep 30, 2021$199.87M–
Q1 FY2021CQ2 2021Jun 30, 2021$186.35M–
Q4 FY2020CQ1 2021Mar 31, 2021$170.28M–

More Roivant Sciences figures

See a number that looks wrong?